IGEA has granted the exclusive license for the Cliniporator® electroporation platform to OncoSec Medical Incorporated within the field of use for DNA-based interleukin-12 (IL-12) gene delivery and other immune-modulatory genes.
Cliniporator® will be used as a part of OncoSec’s visceral lesion applicator (VLA) program to treat non-cutaneous, internal tumors through direct delivery of TAVO™, or other immunologically relevant genes and immunotherapies.
OncoSec is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.
TAVO™ has demonstrated local and systemic anti-tumor response in clinical trials for metastatic melanoma and triple negative breast cancer.
IGEA Cliniporator® is the leading technology for clinical electroporation currently used in over 200 major oncological centers for the treatment of solid tumours with Electrochemotherapy. IGEA has also extensive experience in ElectroGeneTransfer (EGT) applied for the delivery of immunomodulatory and therapeutic genes. IGEA pioneering technology has the potential to lead to important progress in the field of gene therapy.
“The efficiency at which electroporation delivers therapy, along with an incredibly favorable safety profile and ease of use, all make it an ideal choice for drug delivery” said Daniel O’Connor, chief executive officer of OncoSec.
Ruggero Cadossi, M.D., IGEA president, said, “We are proud to collaborate with OncoSec, a company committed to delivering innovative therapies to cancer patients. The culture of knowledge, honesty, moral commitment and the closeness to suffering demands were and will be the guiding light of IGEA.”
Additionally, the U.S. Food and Drug Administration (FDA) has cleared the Cliniporator® for use in the upcoming Phase 1 trial investigating CORVax12, OncoSec DNA vaccine candidate for COVID-19. The CORVax12 vaccine combines the co-administration of plasmid IL-12 with DNA coding for the SARS-CoV-2 spike glycoprotein. This vaccine approach aims at stronger, longer-lasting immune responses and better protection against the virus.